**Data Supplement**

Supplementary Table 1: Demographic characteristics of neurologist and hematologist respondents

|  |  |  |
| --- | --- | --- |
|  | Neurologists, n (%) N=27 | Hematologists, n (%)N=20 |
| ProvinceBritish ColumbiaAlbertaManitobaOntarioQuebecNew BrunswickNova ScotiaNewfoundland | 4 (14.8)5 (18.5)0 (0)6 (22.2)8 (29.6)1 (3.7)2 (7.4)1 (3.7) | 3 (15.0)0 (0)0 (0)14 (70.0)2 (10.0)0 (0)1 (5.0)0 (0) |
| Duration of practice (y)Resident/Fellow<3 3-55-10>10Missing | 1 (3.7)4 (14.8)1 (3.7)6 (22.2)15 (55.6)0 (0) | 0 (0)3 (15.0)1 (5.0)5 (25.0)9 (45.0)2 (10.0) |
| % practice devoted to stroke (CSC) or thrombosis (TC)<1010-2526-5051-75>75Missing | 0 (0)1 (3.7)4 (14.8)7 (25.9)15 (55.6)0 (0) | 0 (0)2 (10.0)5 (25.0)6 (30.0)6 (30.0)1 (5.0) |

Supplementary Table 2: First and second choice of initial anticoagulant for neurologists and hematologists

|  |  |  |  |
| --- | --- | --- | --- |
| *First choice* | Neurologists, n (%)N=27 | Hematologists, n (%)N=20 | p |
| LMWH | 1 (3.7) | 10 (50.0) | 0.002 |
| UFH | 24 (88.9) | 10 (50.0) |
| Warfarin | 1 (3.7) | 0 (0) |
| DOAC | 1 (3.7) | 0 (0) |
| *Second choice* | N=14 | N=16 |  |
| LMWH | 12 (85.7) | 8 (50.0) | 0.01 |
| UFH | 0 (0) | 6 (37.5) |
| Warfarin | 1 (7.1) | 2 (12.5) |
| DOAC | 1 (7.1) | 0 (0) |

Supplementary Table 3: First and second choice of maintenance anticoagulant for neurologists and hematologists

|  |  |  |  |
| --- | --- | --- | --- |
| *First choice* | Neurologists, n (%)N=27 | Hematologists, n (%)N=20 | p |
| LMWH | 2 (7.4) | 5 (25) | 0.24 |
| Warfarin | 23 (85.2) | 14 (70) |
| DOAC | 2 (7.4) | 1 (5) |
| *Second choice* | N=16 | N=19 |  |
| LMWH | 8 (57.1) | 10 (52.6) | 0.59 |
| Warfarin | 2 (12.5) | 5 (26.3) |
| DOAC | 4 (25.0) | 4 (21.1) |